Increase Minus
Friday, May 29, 2020   SENSEX  32424.10  Up  223.51      Asian Paints :   1684.40  Up  40.65      Axis Bank :   383.20  Down  -7.65      Bajaj Auto :   2712.05  Up  115.15      Bajaj Fin. :   1952.70  Up  5.85      Bharti Airtel :   552.40  Down  -10.30      H D F C :   1659.35  Up  33.80      HCL Technologies :   550.40  Up  6.15      HDFC Bank :   951.25  Up  6.20      Hero Motocorp :   2364.90  Up  70.65      Hind. Unilever :   2056.90  Up  47.65      ICICI Bank :   332.10  Up  5.35      IndusInd Bank :   393.30  Up  6.50      Infosys :   691.35  Down  -15.90      ITC :   197.45  Up  6.90      Kotak Mah. Bank :   1223.70  Down  -4.65      Larsen & Toubro :   932.30  Up  29.25      M & M :   436.40  Down  -3.65      Maruti Suzuki :   5612.00  Up  141.45      Nestle India :   17533.85  Up  550.50      NTPC :   97.75  Up  2.00      O N G C :   83.20  Up  4.35      Power Grid Corpn :   157.55  Up  0.20      Reliance Inds. :   1465.20  Down  -7.45      St Bk of India :   160.30  Up  2.00      Sun Pharma.Inds. :   475.45  Up  16.20      Tata Steel :   295.20  Up  0.05      TCS :   1971.55  Down  -33.65      Tech Mahindra :   530.40  Up  0.50      Titan Company :   890.60  Down  -9.20      UltraTech Cem. :   3901.80  Up  91.20    
GET QUOTES NAV NEWS
SENSEX
32424.1
223.51
NIFTY
9580.3
90.20
GOLD
46530
125.00
SILVER
50096
1,538.00
equity
Daily Market Tracker
Gainers & Losers  
Live Indices  
Index Movers  
Advances & Declines  
Value & Volume Toppers  
Only Buyers/Sellers  
Sector Watch  
Bulk Deals  
Block Deals  
New Highs & Lows  
52 Week High & Low  
Out/Under Performers
Index Constituents  
Unusual Volume  
Historical Returns  
News Analysis
Market Analysis
Technical Chart
Company Profile
Other Markets
Corporate Action
Debt Content
Submit Your Query
You Are Here   :  Equity   |   News Analysis  |  hot pursuit  |   Detailed News Back
lupin announces positive chmp opinion for nepexto
Lupin and Mylan N.V. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product. In addition, a phase 3 clinicalstudyiin patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety and immunogenicity.

The CHMP positive opinion will now be considered by the European Commission (EC). Once approved, the EC will grant a centralized marketing authorization for member countries of the EU. The decision on the EC's approval is expected in May 2020.

Enbrel had sales of approximately $9.6 billion globally for the 12 months ending December 2019, according to IQVIA.

In June 2018, Lupin and Mylan announced a collaboration to commercialize a biosimilar to etanercept in several global markets.

Etanercept is an injectable, biologic medicine which inhibits Tumour Necrosis Factor (TNF). TNF is a key cytokine involved in the pro-inflammatory cascade in many chronic, immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis or plaque psoriasis. By specifically binding to TNF, etanercept blocks its activity, thereby reducing inflammation and other disease symptoms.

On a consolidated basis, Lupin reported a net loss of Rs 835 crore in Q3 December 2019 as against a net loss of Rs 151.75 crore in Q3 December 2018. Net sales declined 2.75% to Rs 3,716.09 crore in Q3 December 2019 over Q3 December 2018.

Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The firm offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas.

Shares of Lupin declined 2% to Rs 547 on Friday.

Powered by Capital Market - Live News

  A    |   B   |   C    |  D    |    E    |  F  |    G   |   H  |  I  |    J   |   K  |   L  |    M  |   N  |   O  |   P  |  Q  |  R  |  S  |  T   |  U   |   V   |    W   |  X   |  Y  |    Z
twitter-Small
Left Decrease Increase Right SEBI Equity Reg. No.: INZ000193033   |   Regn. No. NSE: INB/INF/INE 230881235   |   BSE: INB/INF/INE 010881234   |   SEBI Commodity Reg. No.: INZ000028539   |   Membership No.: MCX-10705, NCDEX-0016, ICEX-3003  |   Dubai Gold and Commodity Exchange (DGCX)-3035   |   Indian Energy Exchange (IEX)- Electricity Trading N2DLOAIL0000  |   NSDL- DP ID: IN-DP-NSDL-14-96   |   CDSL DP ID: IN-ID-CDSL-43-99
Copyright@2012 Alankit . All rights reserved. Designed, developed and powered by C-MOTS Infotech (ISO 9001:2015 certified)